LF is not a neglected disease but a priority disease for elimination: Dr. Mandaviya

Global (68M) cardiomyopathies market set to reach $9.63 bn by 2031: GlobalData

The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%

Zydus receives final approval and 180 days shared exclusivity from USFDA for Brexpiprazole tablets

Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults

Sun Pharma launches Palbociclib, a novel targeted therapy for advanced breast cancer

Palbociclib has a unique mechanism of action which helps in delaying disease progression when co-administered with hormonal therapies

Genome sequencing solutions will help to bring precision in lung cancer therapy, says GlobalData

APAC region contributed around 50% of the in-vitro diagnostics market in 2022

Lupin and Exeltis announce reimbursement approval of NaMuscla in Spain

NDM disorders are a group of rare, inherited neuromuscular disorders with an estimated prevalence of 1 case per 100,000 inhabitants in Spain, and are characterized by the inability to relax muscles following voluntary contraction (myotonia)

Zydus receives final approval from the USFDA for Febuxostat Tablets

Febuxostat tablets had annual sales of USD 32 million in the United States according to IQVIA data (IQVIA MAT Sept. 2022).

Lupin receives approval from USFDA for Prasugrel Tablets, USP

Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, (RLD Toviaz®) had estimated annual sales of USD 177 million in the U.S. (IQVIA MAT September 2022).

Zydus launches Topiramate Extended-Release Capsules

Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.